EUVIMED · CrossrefJournal
Drug Discovery Today
ISSN 1359-6446 · Elsevier BV
Latest articles
Synthetic lethality and context-selective DNA-damage response dependencies: from genetic vulnerability to pharmacological translation
Pathway-driven target prioritisation in drug discovery
Chemoproteomics in covalent cancer drug discovery
New insights into FOX proteins in cancer
Advancing a drug-development program is not the same as de-risking it
From artificial intelligence promise to translational practice in drug discovery: Reproducibility, validation and evidence-based implementation
AI-integrated iPSC multi-omics: advancing phenotype discovery and drug target identification in rare diseases
NR4A2: a next-generation drug target orchestrating dynamic gene regulation and protein interactions
Methadone: Historical success, modern challenges and lessons for opioid drug discovery
Aptamer-based therapeutics for malaria and neglected tropical diseases
Advancing interleukin druggability: beyond ligandability toward therapeutic efficacy
Incretin and nutrient-sensing GPCR therapeutics in type 2 diabetes: What target–modality–formulation matching explains
PARP-1 selective inhibitors: A new direction in drug discovery to improve the therapeutic index of PARP-targeted cancer therapy
Networked innovation in the new modality era: strategic insights from spin-offs and precision medicine
Target-state uncertainty in drug discovery: when precise binding data describe the wrong system
The Activity Wall in Alzheimer’s drug discovery: When potency optimization reaches its limits
Medicine’s missing memory: what AI’s mathematical breakthrough reveals about biomedicine
Programmable STING-activating hydrogels for in situ cancer vaccination: Spatiotemporal design and mechanistic evidence
Everything is local: a framework for clinical global assessment in drug development
Harnessing exosomes for breast cancer: bridging conceptual promise to tangible translational application
Rational design and research progress of novel mitochondrial uncouplers
Crosstalk between the cell cycle and ferroptosis in tumor cells
UHRF1-mediated epigenetic dysregulation in tumors: Mechanisms, therapeutic resistance and targeted inhibitors
Tumor hypoxia: Molecular pathways and therapeutic interventions
Universal care under strain: navigating population ageing in Europe
The PROTAC milestone: FDA approval of vepdegestrant (ARV-471) for ESR1-mutated breast cancer
Metabolic reprogramming and drug resistance in hepatocellular carcinoma: The emerging role of SREBP2-driven cholesterol metabolism
Building and managing a complex drug discovery consortium: insights from the tuberculosis drug accelerator
Benign-by-design chemistry: Reinventing ligand-based drug design at the edge of AI
Dermal PBPK modeling in the era of model-informed drug development: Strategies, innovations, and regulatory impact
Volumes
2026 · 2692025 · 2682024 · 2792023 · 3002022 · 3022021 · 3042020 · 2752019 · 2852018 · 2412017 · 2172016 · 2342015 · 2042014 · 2812013 · 1852012 · 1972011 · 1742010 · 2542009 · 1792008 · 1772007 · 1752006 · 1812005 · 3632004 · 3552003 · 3592002 · 4432001 · 4502000 · 1861999 · 1401998 · 1481997 · 1411996 · 230
EUVIMED